Literature DB >> 25242680

Gene expression profiling of peripheral blood mononuclear cells during treatment with a gene-modified allogeneic tumor cell vaccine in advanced renal cell cancer: tumor-induced immunosuppression and a possible role for NF-κB.

Anne Flörcken1, Michael Grau, Annette Wolf, André Weilemann, Joachim Kopp, Bernd Dörken, Thomas Blankenstein, Antonio Pezzutto, Peter Lenz, Georg Lenz, Jörg Westermann.   

Abstract

Tumor-induced immunosuppression remains a major challenge for immunotherapy of cancer patients. To further elucidate why an allogeneic gene-modified [interleukin-7 (IL-7)/CD80-cotransfected] renal cell cancer (RCC) vaccine failed to induce clinically relevant TH-1-polarized immune responses, peripheral blood mononuclear cells from enrolled study patients were analyzed by gene expression profiling (GEP) both prior and after vaccination. At baseline before vaccination, a profound downregulation of gene signatures associated with antigen presentation, immune response/T cells, cytokines/chemokines and signaling/transcription factors was observed in RCC patients as compared to healthy controls. Vaccination led to a partial reversion of preexisting immunosuppression, however, GEP indicated that an appropriate TH-1 polarization could not be achieved. Most interestingly, our results suggest that the nuclear factor-kappa B signaling pathway might be involved in the impairment of immunological responsiveness and the observed TH-2 deviation. In summary, our data suggest that GEP might be a powerful tool for the prediction of immunosuppression and the monitoring of immune responses within immunotherapy trials.
© 2014 UICC.

Entities:  

Keywords:  NF-κB; gene expression profiling; immune response; renal cell cancer; tumor vaccination

Mesh:

Substances:

Year:  2014        PMID: 25242680     DOI: 10.1002/ijc.29230

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  2 in total

1.  JAK2 inhibitor combined with DC-activated AFP-specific T-cells enhances antitumor function in a Fas/FasL signal-independent pathway.

Authors:  Yang Liu; Yue-Ru Wang; Guang-Hui Ding; Ting-Song Yang; Le Yao; Jie Hua; Zhi-Gang He; Ming-Ping Qian
Journal:  Onco Targets Ther       Date:  2016-07-20       Impact factor: 4.147

2.  Induction and characterization of anti-tumor endothelium immunity elicited by ValloVax therapeutic cancer vaccine.

Authors:  Samuel C Wagner; Thomas E Ichim; Vladimir Bogin; Wei-Ping Min; Francisco Silva; Amit N Patel; Santosh Kesari
Journal:  Oncotarget       Date:  2017-04-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.